Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

Lebwohl, Mark; Bachelez, Hervé; Barker, Jonathan; Girolomoni, Giampiero; Kavanaugh, Arthur; Langley, Richard; Paul, C.; Puig, Lluís; Reich, Kristian; Kerkhof, P.C.M. van de

doi:10.1016/j.jaad.2013.12.018

Cited by 443 publications

(550 citation statements)

References 37 publications

Supporting

Mentioning

510

Contrasting

Unclassified

Order By: Relevance

“…Abt SRBI, Inc. (New York, NY, USA) conducted the MAPP survey between June and August 2012 [22]. Via telephone, Abt SRBI staff surveyed households in the USA, Canada, France, Germany, Italy, Spain, and the UK.…”

Section: Methodsmentioning

confidence: 99%

“…The clinical presentation of PsA varies. It occurs in approximately 30% of patients with psoriasis [4,12,16,25,28] and typically follows the onset of psoriasis by approximately 8-10 years [12,22].…”

Section: Introductionmentioning

confidence: 99%

“…The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP), a population-based survey of 3426 patients and nearly 781 physicians in North America and Europe, is the largest probability survey of psoriatic disease conducted to date [22,23,34]. Here, we explore the results compiled from the subset of patients with PsA participating in the MAPP survey.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey

2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey

2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, improvements in pruritus severity were rapid, both upon initial treatment and upon re‐treatment. This finding is particularly pertinent given recent reports from a population‐based survey, in which 43% of more than 3000 patients with psoriasis indicated that pruritus was the most bothersome symptom 10, 34. In addition, pruritus is more likely to result in the absence from work than pain or scaling, and leads to reduced productivity 35.…”

Section: Discussionmentioning

confidence: 91%

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Griffiths

Vender

Sofen

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundTofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. A Phase 3 withdrawal/re‐treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re‐treatment was effective in patients with chronic plaque psoriasis.ObjectivesTo describe the effects of tofacitinib withdrawal/re‐treatment on health‐related quality of life (HRQoL) and disease symptoms measured by patient‐reported outcomes (PROs).MethodsThe study was divided into initial treatment, treatment withdrawal, and re‐treatment periods. Initial treatment: patients were randomized to receive tofacitinib 5 (n = 331) or 10 mg (n = 335) BID for 24 weeks. Treatment withdrawal: patients who achieved both ≥ 75% reduction in Psoriasis Area and Severity Index (PASI) score from baseline and Physician's Global Assessment of ‘clear’/‘almost clear’ at Week (W)24 received placebo (withdrawal) or the previous dose (continuous treatment). Re‐treatment: at relapse (> 50% loss of W24 PASI response) or at W40, patients received their initial tofacitinib dose. PROs included: Dermatology Life Quality Index (DLQI), Itch Severity Item (ISI), Short Form‐36 (SF‐36) and Patient's Global Assessment (PtGA).ResultsAfter initial treatment with tofacitinib 5 and 10 mg BID, substantial and significant improvements were reported for mean DLQI (baseline: 12.6 and 12.6; W24: 5.1 and 2.6) and ISI (baseline: 6.7 and 6.9; W24: 2.9 and 1.6). Patients continuously treated with tofacitinib 5 and 10 mg BID maintained those improvements through Week 56 (DLQI: 3.0 and 2.1; ISI: 2.3 and 1.4). By W40, patients withdrawn from tofacitinib 5 and 10 mg BID showed worsening in DLQI (5.0 and 6.2) and ISI (3.7 and 4.0) scores; improvements were regained upon re‐treatment (W56, DLQI: 3.4 and 2.4; ISI: 2.2 and 1.6). Similar results were reported for PtGA and SF‐36.ConclusionContinuous tofacitinib treatment provided sustained improvement in HRQoL and disease symptoms. Patients randomized to treatment withdrawal lost initial improvements. Upon re‐treatment, improvements were recaptured to levels comparable to those seen with continuous treatment.

show abstract

“…Patients exhibit a wide spectrum of symptoms, including itching, pain and scaling of varying severity 2, 3. The impact of psoriasis can be substantial on health‐related quality of life (HRQOL) and is typically lifelong unless the patient receives highly effective therapy 4.…”

Section: Introductionmentioning

confidence: 99%

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

Blauvelt

Reich

Mehlis

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundPsoriasis can greatly impact patients’ lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin‐17A, has demonstrated good efficacy and safety in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response.ObjectiveThis analysis using the CLEAR study, a phase 3b double‐blind study comparing the efficacy and safety of secukinumab vs. ustekinumab in adults with moderate‐to‐severe plaque psoriasis, evaluated the treatment effects on patient's daily activities and personal relationships.MethodsImpact on daily activities (interference with home/shopping/garden, and influence on clothes worn) and impact on personal relationships (problems with partner/others, and sexual difficulties) as well as their corresponding subscales were selected from the Dermatology Life Quality Index scale and evaluated for patients treated with secukinumab vs. ustekinumab from the CLEAR study. Treatment differences in mean scores and proportions of responders (score = 0, indicating no impact) were evaluated through 52 weeks. Time to response was evaluated through Week 16.ResultsSignificant differences between secukinumab and ustekinumab were observed for daily activities and personal relationships at Week 16 and sustained through Week 52 (Week 52 response rates for daily activities: 82.9% vs. 73.5%, including interference with home/shopping/garden: 88.5% vs. 78.2%, and influence on clothes worn: 85.6% vs. 74.4%; personal relationships: 86.1% vs. 73.7%, including problems with partner/others: 86.6% vs. 74.8%, and sexual difficulties: 88.5% vs. 74.3%; all P < 0.01). The median time to response was 4 weeks for secukinumab vs. 8 weeks for ustekinumab for daily activities and personal relationships (both P < 0.05).ConclusionSecukinumab treatment helps patients with moderate‐to‐severe plaque psoriasis have a more normal life faster when compared to ustekinumab, by providing greater and sustained improvement in clothing choice and sexual functioning.

show abstract

Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

Cited by 443 publications

References 37 publications

Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey

Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

Contact Info

Product

Resources

About